Organic compounds -- part of the class 532-570 series – Organic compounds – Oxygen containing
Patent
1994-08-09
1996-10-22
Richter, Johann
Organic compounds -- part of the class 532-570 series
Organic compounds
Oxygen containing
C07C 4311
Patent
active
055678599
ABSTRACT:
The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but substantially reduce the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable and the cardiotoxicity inherent in the native copolymers is substantially reduced.
REFERENCES:
patent: 4764567 (1988-08-01), Ott
Database WPI, Derwent Publications Ltd., London, GB; AN 82-14781E(08) & JP-A-57 008 223 (mitsui Petrochem.) 16 Jan. 1982. *abstract only*.
Schick, M. J., Non-ionic Surfactants, Marcel Dekker Inc., New York, pp. 893-920 (1967).
Schmolka, I., "A Review of Block Polymer Surfactants," Journal of the American Oil Chemists Society, 54, No. 3, pp. 110-116 (1977).
Block and Graft Copolymerization, vol. 2, (ed. by R. J. Ceresa, John Wiley & Sons, 1976) "The Applications of Block Copolymer Polyol Surfactants," L. G. Lundsted and I. R. Schmolka; pp. 174-205 and pp. 255-272 (references).
Reindorf, C. A., et al., "Perfluorocarbon Compounds: Effects on the Rheological Properties of Sickle Erythrocytes in vitro," American Journal of Hematology, vol. 19, pp. 229-236 (1985).
Padilla, F., et al., "Effect of Fluorocarbon emulsions on the mechanical fragility of normal and sickle cells: in vitro studies," Federation Proceedings, vol. 34, pp. 1510-1512 (1975).
Vercellotte, G. M., et al., "Activation of Plasma Complement by Perfluorocarbon Artificial Blood: Probable Mechanism of Adverse Pulmonary Reactions in Treated Patients and Rationale for Corticosteroid Prophylaxis," Blood, vol. 59, pp. 1299-1304 (1982).
Rodeheaver, G. T., "Pluronic.RTM. F-68: A Promising New Skin Wound Cleanser," Ann Emerg, Med., 9:11, pp. 572-576 (1980).
Janoff, A. S., et al., "The Modification of Human Erythrocyte Membrane Structure by Membrane Stabilizers: An Electron Spin Resonance Study," American Journal of Hematology, vol. 10, pp. 171-179 (1981).
Moore, A. R., et al., "Reduction of Splenic Vascular Resistance During Profusion By Pluronic.RTM. F-68," Journal of Surgical Research, vol. 8, pp. 563-566 (1968).
Benner, K. U., et al., "Cold-Induced Platelet Aggregation In Vivo And Its Inhibition By A Nonionic Surface Active Substance," Thrombosis Research, vol. 2, pp. 331-342 (1973).
Hymes, A. C., et al., "The Influence Of An Industrial Surfactant Pluronic.RTM. F-68, In The Treatment of Hemorrhagic Shock," Journal of Surgical Research, vol. 11, pp. 191-197 (1971).
Hoie, J., et al., "Effects of Pluronic.RTM. F68, Poloralkol, On Vascular Resistance In Vivo," Journal of Surgical Research, vol. 11, pp. 515-517 (1971).
Grover, F. L. et al., "A Nonionic Surfactant And Blood Viscosity," Arch. Surg., vol. 106, pp. 307-310 (1973).
Grover, F. L. et al., "The Effect of Pluronic.RTM. F-68 On Circulatory Dynamics And Renal And Carotid Artery Flow During Hemorrhagic Shock," Journal of Surgical Research, vol. 17, pp. 30-35 (1974).
Ketchum, L. D. et al., "Experimental Use of Pluronic.RTM. F-68 In Microvascular Surgery," Plastic and Reconstructive Surgery, vol. 53, pp. 288-292 (1974).
Ketchum, L. D., "Pharmacological alternations in the clotting mechanism: Use in microvascular surgery," Journal of Hand Surgery, vol. 3, pp. 407-415 (1978).
Vasco, K. A., et al., "Poloxalkol.RTM. (Pluronic F-68): A priming solution for cardiopulmonary bypass," Trans. Am. Soc. Artif. Int. Organs, 18, 526-531 (1972).
Block, N. L., et al., "Acutely Traumatized canine ureter, Effects of low molecular weight dextran and surfactant Pluronic F-68," Urology, vol. III 190-194 (1974).
Knize, D. M., et al., "Use of antisludging agents in experimental cold injuries," Surgery, Gynecology & Obstetrics, vol. 129, pp. 1019-1026 (1969).
Paton, B. C., et al., Organ Perfusion and Preservation, (ed. by Norman, J. C., Appleton-Centry-Crofts (1968), "The use of a nonironic detergent added to organ perfusates," pp. 105-120.
Smillie, J. A., et al., "Cryopreservation of Human Platelets with Polyvinylpyrrolidone," Transfusion, vol. 21, pp. 552-556 (1981).
Gaehtgens, P., et al., "Disaggregation of Human Red Blood Cells by Various Surface-Active Agents as Related to Changes of Cell Shape and Hemolysis," Act Heamat., vol. 33 pp. 82-89 (1975).
Sugi, et al., "The use of Fluosol-DA (FDA) in emergency situations: a report of 67 clinical cases," Abstract/451. Advances in Blood Substitute Research ed. by Bolin, et al., Alan R. Liss, Inc. New York (1983).
Lane, T. A., et al., "Reduction in the toxicity of a component of an artificial blood substitute by supercritical fluid fractionation," Transfusion, vol. 28, pp. 375-378 (1987).
Lane, T. A., et al., "Paralysis of Phagocyte migration due to an artificial blood substitute," Blood, vol. 64, pp. 400-405 (1984).
Spiess, B. D., et al., "Protection from cerebral air emboli with perfluorocarbons in rabbits," Stroke, vol. 17, pp.b 1146-1149 (1986).
Kanter, K. R., et al., "Superiority of perfluorocarbon cardioplegia over blood or crystalloid cardioplegia," Circulation, vol. 64. II75-II80 (1981).
Harjula, A., et al., "Perfluorocarbon solution as a myocardial preservative," J. Applied Cardiology, vol. 2, pp. 121-136 (1987).
Tokioka, M. D., et al., "Effects of introcoronary infusion of arterial blood or Fluosol-DA 20% on regional myocardial metabolism and function during brief coronary artery occlusions," Laboratory Investigation, vol. 75, pp. 473-481 (1987).
Forman, M. B., et al., "Reduction of infarct size within intracoronary perfluorochemical in a canine preparation of reperfusion," Circulation, vol. 71, pp. 1060-1068 (1985).
Forman, M. B., et al., "Beneficial long-term effect on intracoronary perfluorochemical on infarct size and ventricular function in a canine reperfusion model," J. Am. Col. of Cariol, pp. 1082-1090 (May 1987).
Goodman, R. L., et al., "Perfluorocarbon emulsions in cancer therapy: preliminary observations on presently available formulations," Int. J. Radiation Oncology Viol. Phys., vol. 10, pp. 1421-1424 (1984).
Perfluorochemical Blood Substitutes, Technical Information Ser. No. 5, Jun. 30, 1978, Revised, Jul. 1, 1981, Manufacturer: The Green Cross Corporation.
Connaghan et al., "Specific Identifications of Fibrin Polymers, Fibrinogen Degradation Products, and Cross linked Fibrin Degration Products in Plasma and serum with a New Sensitvie Technique," Blood, vol. 65, No. 3, pp. 589-597 (Mar. 1985).
Atkinson et al., "Iontransport mediated by copolymers composed of polyoxyethylene and polyoxypropylene," The American Physiological Society, 0363-6143/88, pp. C20-C26 (1988).
Wiman et al., "Determination of Soluble Fibrin in Plasma by a Rapid and Quantitative Spectrophotometric Assay," Thrombosis and Haemostasis, F. K. Schattauer Verlag GmbH (Stuttgart) 55(2), pp. 18-193 (1986).
Hunter et al., "The Adjuvant Activity of nonionic Block Polymer Surfactanst," Scand. J. immunol., No. 23, pp. 287-300 (1986).
Hunter et al., "The Adjuvant Activity of Nonionic Block Polymer Surfactants. I. The Role of Hydrophile-Lipophile Balence," J. Immunol., vol. 127, No. 3, pp. 1244-1250 (1981).
Hunter et al., "Nonionic block copolymer surfactants as immunological adjuvants: Mechanisms of action and novel formulation," Immunological Adjuvants and Vaccines, ed. Gregoriadis et al., Plenum Publishing Corp., pp. 133-144 (1989).
Byars et al., "Adjuvant Formulation for Use in Vaccines to Elicit cell-Mediated and Humoral Immunity," Vaccine, vol. 5, pp. 223-228 (Sep. 1987).
Allaudeen Hameedsulthan S.
Balasubramanian Mannarsamy
Emanuele R. Martin
Cytrx Corporation
Peabody John
Richter Johann
LandOfFree
Polyoxypropylene/polyoxyethylene copolymers with improved biolog does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyoxypropylene/polyoxyethylene copolymers with improved biolog, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyoxypropylene/polyoxyethylene copolymers with improved biolog will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2359749